<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526798</url>
  </required_header>
  <id_info>
    <org_study_id>No 1491 CIEPO-PILOT</org_study_id>
    <nct_id>NCT01526798</nct_id>
  </id_info>
  <brief_title>Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis</brief_title>
  <acronym>CIEPO-PILOT</acronym>
  <official_title>Improvement of EPO-resistance in HD Patients With Chronic Inflammation by High Cut-off Hemodialysis - Pilot Study (CIEPO-PILOT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gambro Dialysatoren GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic inflammation in dialysis patients is linked to cardiovascular mortality and clinical&#xD;
      signs and symptoms, like the impaired response to erythropoiesis-stimulating agents (ESAs).&#xD;
      This study aims to demonstrate that high cut-off hemodialysis is effective in reducing&#xD;
      chronic inflammation and thereby improving response to ESAs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic inflammation in hemodialysis patients (micro-inflammation) is caused by multiple&#xD;
      inflammatory stimuli and becomes apparent by elevated levels of biochemical markers such as&#xD;
      CRP, IL-6, cellular activation markers etc. Chronic inflammation is linked to clinical signs&#xD;
      and symptoms and cardiovascular mortality in dialysis patients. Inflamed dialysis patients&#xD;
      show impaired response to erythropoiesis-stimulating agents (ESA) related to reduced iron&#xD;
      utilization (functional iron deficiency) and elevated CRP levels are associated with a&#xD;
      greater need for ESA to meet hemoglobin targets. If absolute iron deficiency can been&#xD;
      excluded, EPO resistance is likely related to 'inflammatory block'.&#xD;
&#xD;
      The high molecular permeability of the Theralite high cut-off membrane allows for significant&#xD;
      clearance of cytokines and other pro-inflammatory solutes by hemodialysis as shown in&#xD;
      previous trials with high cut-off dialyzers. The study therefore aims to demonstrate that&#xD;
      Theralite dialysis is effective in reducing chronic inflammation in ESRD patients, thereby&#xD;
      improving EPO responsiveness. If this can be demonstrated, application of Theralite&#xD;
      hemodialysis may reduce morbidity and mortality in the long term in ESRD patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythropoietin (EPO) resistance index</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Weekly EPO dose in international units (IU) per kg body weight divided by hemoglobin value in g/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high sensitivity C-reactive protein (CRP), hepcidin, Free Light Chains (FLC), Interleukin (IL)-6, Interleukin (IL)-10</measure>
    <time_frame>baseline, 4, 8 and 12 weeks</time_frame>
    <description>Change in pre-dialysis concentration over study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea, Hepcidin, Free Light Chains, IL-6, IL-10</measure>
    <time_frame>baseline, week 1</time_frame>
    <description>Pre- and post-dialysis concentration of urea, hepcidin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>baseline, weeks 2,4,6,8,10,12,14,16,18,20,22,24</time_frame>
    <description>Pre-dialysis albumin concentration during study period and follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>End-Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>Therlite hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group hfHDF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group hfHDF</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theralite (high cut-off hemodialysis)</intervention_name>
    <description>Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer</description>
    <arm_group_label>Therlite hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional high-flux dialyzer</intervention_name>
    <arm_group_label>Control group hfHDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ESRD treated with chronic HD for at least 3 months&#xD;
&#xD;
          -  Treatment with high-flux dialyzers for at least 3 months&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Receiving ESA to treat anemia for at least 3 months&#xD;
&#xD;
          -  Impaired ESA responsiveness as indicated by EPO resistance index &gt; median of patients&#xD;
             in study center&#xD;
&#xD;
          -  Transferrin saturation (TSAT) ≥20% (last routine value prior to randomization)&#xD;
&#xD;
          -  Serum ferritin ≥100 ng/ml (last routine value prior to randomization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute infection ≤4 weeks prior to randomization&#xD;
&#xD;
          -  HIV or hepatitis infection&#xD;
&#xD;
          -  Catheter&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Known blood dyscrasia (paraprotein abnormalities)&#xD;
&#xD;
          -  Known bleeding disorders&#xD;
&#xD;
          -  Bleeding episode ≤12 weeks prior to randomization&#xD;
&#xD;
          -  Blood/red cell transfusion ≤12 weeks prior to randomization&#xD;
&#xD;
          -  Hypoalbuminemia defined as serum albumin concentration below 35 g/L (last routine&#xD;
             value prior to randomization)&#xD;
&#xD;
          -  Participation in another clinical interventional investigation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Planned transplantation within study period +3 months&#xD;
&#xD;
          -  Planned interventions requiring hospitalization &gt;1 week&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ugo Teatini, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Garbagnate Milanese Ospedale Bollate - Divisione Nefrologia e Dialisi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Garbagnate Milanese Ospedale Bollate - Divisione Nefrologia e Dialisi</name>
      <address>
        <city>Bollate</city>
        <state>Milan</state>
        <zip>20021</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End-Stage Renal Disease (ESRD)</keyword>
  <keyword>chronic Inflammation</keyword>
  <keyword>EPO Resistance</keyword>
  <keyword>ESA Resistance</keyword>
  <keyword>high cut-off dialysis</keyword>
  <keyword>hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

